Prostate Adenocarcinoma

A new study developed and validated a non-invasive urine DNA methylation assay for prostate cancer detection, aiming to improve the specificity of PSA screening. This test, based on the methylation of two genes (ADD3 and GSX2), was developed retrospectively in 348 participants and prospectively validated in 200 participants in a multicenter study. It demonstrated robust diagnostic performance with AUCs of 0.86 and 0.91, and specificity above 90%. Integrating this tool could potentially avert approximately 55% of unnecessary biopsies without compromising cancer detection.

This study investigates how altered enhancers in prostate cancer cooperate within the 3D chromatin architecture to drive oncogenic programs. Researchers identified prostate cancer-specific enhancers that form highly nested interactions with promoters, coalescing into multi-connected hubs. CRISPR/Cas9 perturbations distinguished distinct enhancer classes: central enhancers, whose deletion collapses hub-wide activity and impairs cell proliferation, and redundant enhancers, whose deletion has minimal impact due to compensatory architectural rewiring. The transcription factor FOXA1 was found to directly bind and regulate these distinct enhancer classes. These findings suggest that enhancers function in a coordinated manner and open new avenues for precision therapies.